BNGO Bionano Genomics Inc

$BNGO In 6 years Bionano has gone from 3 million a quarter to 8 million a quarter in revenue, while burning though a half of billion dollars of shareholder money while reverse splitting twice and they will be out of cash in a few more months. Anybody that invest in this company is a stupid moronic idiot

$BNGO The worst investment of my life, not much but still criminal. This company should vanish from the earth .

$BNGO $PACB PacBio tried to bury the FSHD map. Their own data does not do it. Oct 8 post is Kivvi, a HiFi tool for the D4Z4 repeat. It called 11 of 11 contracted alleles, checked against Southern blot on 27 controls and OGM on 10 GeneDx FSHD1 samples. A tool paper. Then the pitch: OGM is slow, blood only, wait for a batch, no methylation, so buy the sequencer. Stratys does not batch. Twelve single-sample chips. Load one. Unload it when it finishes. The slow part is the DNA prep. Ionic fixes that. Isotachophoresis, eight samples, about two hours, already shown pulling OGM-grade DNA from blood and marrow. Methylation is the one they have. OGM does not call 5mC. FSHD2 still wants it. OGM’s job is the blot’s job: repeat count, haplotype, 4 versus 10. EnFocus is 100% concordant with Southern blot on that count. A methylation number does not replace the map. It sits next to it.

$BNGO Shorts piled in after the bounce. Official short interest sat near 1.2 million shares (~11% of the float) all summer. After the $1.00 low and $2.23 on ~39 million shares, estimates jumped to ~2.1 million (~20%+). That is new shorts selling the rip. The last official report is still ~11%. The next one tells us if they added or covered. A squeeze is simple: they borrowed stock and sold it. To get out they have to buy it back. ~10.6 million shares in the float. On a quiet day that book took a week to cover. After a 39-million-share day it’s a fight to borrow. Why they’re leaning against the wrong tape: 81195 pays $1,853.22. Q2 chips +27%. New York cleared OGM lab tests. MolDX heme draft is out (not final yet). Company slide: $50–54M in 2027, ~$100M in 2029. Cap is still tiny. $1.75 is the first bounce off $1. Shorts added. The map is getting paid. Squeeze is the spark. The flywheel is the reason they have to buy it back.

$BNGO ASHG 2026: Bionano previewing automated first step of OGM workflow (upstream of chip load) to industrialize prep. Booth #810. Meet-the-Expert w/ Alexander Hoischen (Radboudumc) Thu 3:30–4:30. Stratys/Saphyr/VIA on floor. Hoischen’s group already published OGM in heme, constitutional & large repeats; prior work showed automated UHMW isolation (Hamilton) preserves length + cuts hands-on time. Front-end automation is the remaining bottleneck for higher-volume labs. Demand already outpaces flow-cell supply. Routine sites drive consumable pull-through. Live 81195 ($1,853.22) + 81354, MolDX proposed LCD open, NYSDOH at Rochester + MSK. Walk-away prep lets the same installed base run more samples without linear headcount. Utilization compounds on boxes already in the field.

$BNGO Sources say, Erik Holmlin resigned due to complications with his most recent “ARS” (Anal Reconstruction Surgery). His aDickshun to Phalus shaped Peloton accessories got completely out of control. Not judging………

$BNGO What's happening here? What did they do now? Did the dasholes issue more shares again?

$BNGO your st footprint is less than18 months old and you're posting about six year old news. nice try.

$BNGO you said offering was definitely comming by last friday...i sold everything at a loss because of your post. what happened?

$BNGO It's highly likely that the company will raise the much needed cash by lowering the warrants conversion price from$2 to 1 while issuing additional warrants with a new conversion price of $1.